01—Abstract
Summary
Summary of the 8-K filed May 5, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on May 5, 2023, detailing the results of its 2023 Annual Meeting of Stockholders held on May 3, 2023.
The filing confirms the election of three Class II directors: Stephen Berenson, Sandra Horning, M.D., and Paul Sagan, all for three-year terms. Additionally, stockholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The meeting also saw a shareholder proposal requesting a report on the feasibility of transferring intellectual property.
This proposal was not approved by the majority of the votes cast. Overall, the results indicate strong support for the company's board of directors, executive compensation practices, and auditor selection, while a shareholder-initiated proposal did not gain majority approval.
02—Key points
Key Highlights
- Moderna's 2023 Annual Meeting of Stockholders was held on May 3, 2023, with a quorum present.
- Stephen Berenson, Sandra Horning, M.D., and Paul Sagan were elected as Class II directors for three-year terms.
- Stockholders approved, on an advisory basis, the compensation of Moderna's named executive officers.
- The appointment of Ernst & Young LLP as the independent registered public accounting firm for FY2023 was ratified.
- A shareholder proposal seeking a report on intellectual property transfer feasibility was voted down by a significant margin.
- No other business matters were presented or voted on at the meeting.
03—Questions
Frequently Asked Questions
What were the key outcomes of Moderna's 2023 Annual Meeting of Stockholders?
The key outcomes include the election of three directors, advisory approval of executive compensation, ratification of the independent auditor (Ernst & Young LLP), and the rejection of a shareholder proposal regarding intellectual property transfer feasibility.
Which directors were elected and for what term?
Stephen Berenson, Sandra Horning, M.D., and Paul Sagan were elected as Class II directors for a three-year term, expiring at the Company's 2026 Annual Meeting of Stockholders.
What was the outcome of the shareholder proposal regarding intellectual property?
The shareholder proposal requesting a report on the feasibility of transferring intellectual property was not approved by the stockholders. The 'Votes Against' significantly outnumbered the 'Votes For'.
Is the approval of executive compensation binding?
No, the approval of executive compensation is on a non-binding advisory basis, meaning it provides an indication of shareholder sentiment but does not legally bind the company's board.
04—Continue